The Research Center for Clinical Neuroimmunology and Neuroscience Basel is an interdisciplinary research institution supported by a non-profit foundation.
Basel
Joined February 2022
- Tweets123
- Following79
- Followers143
- Likes217
RC2NB retweeted
Yes👍 from @SofiaSandgren1 @JensKuhle @RC2NB @UniBasel: Blood NfL can provide information on disease activity, prognosis and treatment response, both in drug development trials and in personalised medicine in #MultipleSclerosis.
🔽
journals.sagepub.com/doi/abs…
2/🧵
RC2NB retweeted
John Dystel Prize for Multiple Sclerosis Research awarded to Dr. Ludwig Kappos for his transformative contributions to MS research
eurekalert.org/news-releases…
Our latest Annual Report is out 🚀
Full of insights, milestones, and momentum through research, data innovation, and collaboration.
👉 Get it here: rc2nb.ch/media-and-downloads…
RC2NB retweeted
In #MultipleSclerosis, treatment effects on blood neurofilament light chain #NfL are moderately associated with therapeutic effects on relapses and MRI lesions.
A meta-regression of randomized controlled trials from @RC2NB @UniBasel_en @unige_en ▶️ journals.sagepub.com/doi/abs…
RC2NB retweeted
OCT availability and routine use by neurologists is limited in Switzerland. Awareness, education and guidelines on its clinical use in the care of people with #MultipleSclerosis.
🔓MSJ-ETC study from @Unispital_USZ @RC2NB ▶️ journals.sagepub.com/doi/ful…
RC2NB retweeted
Deep learning can automate the classification of paramagnetic rim and remyelinated lesions in #MultipleSclerosis, guiding personalized treatment decisions.
Study from @CristinaGranzi2 @RC2NB ▶️ journals.sagepub.com/doi/abs…
🎉 Congratulations to Prof. @JensKuhle , Head of the MS Centre @usb_ch and Group Leader @RC2NB, for being named one of Clarivate’s Highly Cited Researchers 2025, ranking among the top 1% most cited scientists worldwide.
#HighlyCited2025 #ResearchExcellence #Neuroscience
RC2NB retweeted
New study in Science Translational Medicine (@ScienceMagazine) from @akproebstel and colleagues reveals distinct immune signatures in MOG antibody–associated disease (MOGAD), distinguishing it from MS. Researchers from Zurich, Munich, Toulouse, Lyon, Bonn & Basel (@DepBiomedicine, @DKFBasel, @RC2NB) uncover key immune differences shaping future therapies.
👉🏻 Link: science.org/doi/10.1126/scit…
#MOGAD #MSResearch #Neuroinflammation
ALT Visual representation of neuroinflammation: red, reactive immune activity disrupting the normal blue neural network. The image symbolizes the immune dysregulation underlying MOG antibody–associated disease (MOGAD). Image Adobe Stock.
New study led by David Leppert, Roberto Furlan & @JensKuhle shows that specific CSF markers can distinguish MOGAD & NMOSD from MS.
A fast, biology-driven approach for accurate diagnosis in acute demyelination.
academic.oup.com/brain/advan…
#MS #MOGAD #NMOSD #Biomarkers
🧪 New data from the phase 3 POINT study: combining ponesimod + dimethyl fumarate in relapsing MS did not improve relapse rate, but reduced MRI lesion activity vs DMF alone. Safety was consistent with known profiles.
📄 sciencedirect.com/science/ar…
RC2NB retweeted
MSIF is proud to announce Professor Ludwig Kappos as the 2025 #CharcotAward recipient, honouring a lifetime of impact in #MSResearch. 🏆🔬
From pioneering treatments to mentoring researchers worldwide, his legacy is global. 🌎
Read more: msintfederation.org/4ncra5K
@RC2NB
🚀 Our new website is live!
Explore RC2NB's research, people & purpose — now at RC2NB.ch 🧠✨
🎬 Watch the RC2NB Welcome Video for a glimpse into our world.
▶️ vimeo.com/1090750659/1325893…
#RC2NB #Neuroimmunology #MSResearch #WebsiteLaunch
RC2NB retweeted
Functional System scores and their corresponding subscores, Ambulation scores and EDSS scores revealed different patterns of disability in #MultipleSclerosis.
Machine learning study using EXPAND trial from @RC2NB @UniBasel_en @UniSpitalBasel ▶️ journals.sagepub.com/doi/ful…
🧠 New in Neurol Neuroimmunol Neuroinflamm:
CSF TNF markers + early gray matter damage predict PIRA in early RRMS.
Key predictors: sTNFR1, sTNFR2, LIGHT, cortical lesions, thalamic atrophy.
🔗pubmed.ncbi.nlm.nih.gov/4031…
#MS #PIRA #Neuroinflammation #MRI #CSF #MultipleSclerosis
RC2NB retweeted
Just 24 participants to go:
Our Swisswide pragmatic #MultiSCRIPT trial is close to reaching 915 in about a year.
Only possible through full embedding in routine care and with an outstanding team @RC2NB and #SMC and the wonderful support of our patients.
multiscript.rc2nb.ch/
In RC2NB’s Annual Report, real patient stories highlight why personalized treatments & cutting-edge research matter. Together, we’re shaping the future of MS care. #MS #Research #PatientVoices
We are pleased to present the @RC2NB Annual Report 2024, highlighting a year of progress, key milestones, and scientific advancements across our four core workstreams. 📖 Read the full report here: rc2nb.ch/wp-content/uploads/…
Feb 11 – International Day of Women & Girls in Science! 🚀 At #RC2NB & @ThINk_Basel , this day is every day. Leading the way? Prof. Cristina Granziera, championing brilliant women who shape the future of #STEM.🔬💡 #WomenInScience #IDWGS #MSresearch
@RC2NB joined the MS State of the Art Symposium 2025 on "Lifestyle in MS: Sports, Nutrition, & Brain Health."
Proud to see @ThINk_Basel & @JensKuhle represent RC2NB, with our team sharing research on:
🔬 MultiSCRIPT
🔬 Complement activation in MS
🔬 B cell therapies
